FinVector selects Elomatic to provide project management for new pharmaceutical plant

FinVector Oy, a leading developer of viral-based gene therapy products, has chosen Elomatic Oy as the consultant for the construction of its new pharmaceutical facilities to be built in Kuopio, Finland.

The two companies signed a project management agreement on October 13th for FinVector’s new pharmaceutical production plant investment to be built in Kuopio. Construction has already started, and the production facility is due for completion at the beginning of 2024. 

The agreement consists of project management, procurement, expediting deliveries and commissioning and qualification management for the construction project. Elomatic will also be responsible for the cleanroom and the acquisition of single-use production equipment for FinVector’s tailor-made, high-value pharmaceuticals.

Elomatic was selected as the project management partner thanks to its ability to deliver full-scope service that FinVector needed at short notice,” says Tony Lönnbäck, Capital Project Director at FinVector. The two companies have also successfully collaborated on other projects in the past.

FinVector develops treatment for patients with superficial bladder cancer. The new facility will be ready to continue the series of virus-based gene therapy products.

“It is great that new medicines are being developed and that companies continue to invest in Finland. We are really happy to be involved in this project to help FinVector on this important mission,” says Mona Åkerholm, Senior Vice President at Elomatic.

Further information:

Mona Åkerholm, Senior Vice President, Pharma
Tel. +358 50 477 2871

Elomatic Oy is a Finnish consulting and engineering company with more than 30 years of experience in pharmaceutical industry projects and investment project management. In addition, the company provides demanding expert services to the process, machinery and maritime industries, among others. Elomatic focuses on continuous improvement and energy-saving solutions. The privately owned company employs more than 1,200 professionals around the world.

FinVector Oy, part of the Ferring Ventures Group based in Kuopio, Finland, is the world’s leading research and product developer and manufacturer of viral-based gene therapy products. Founded in Kuopio in 1993, the company currently operates four independent operation suites. It is building a fifth production suite in a greenfield manufacturing plant close to its facilities.